AVI BioPharma to Present at TIDES Meeting
May 20 2008 - 9:30AM
Marketwired
PORTLAND, OR today announced that Patrick Iversen, Ph.D., AVI's
Senior Vice President of Strategic Alliances, is presenting at the
TIDES Oligonucleotide and Peptide Technology and Product
Development meeting in Las Vegas on Tuesday, May 20, 2008. The
title of his presentation is "Manipulating the Immune Response with
Cell Penetrating Peptide Conjugated Phosphorodiamidate Morpholino
Oligomers" and is to feature the targeting of genes, such as
interleukin-10 (IL-10), involved in the host immune response, with
AVI's proprietary Phosphorodiamidate Morpholino Oligomers and
arginine-rich peptides. IL-10 is considered a key regulator of
immune response to infection from viruses, bacteria and other
organisms.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NeuGene� antisense
drugs and ESPRIT directed RNA alternative splicing technology.
AVI's ESPRIT technology is initially being applied to potential
treatments for Duchenne muscular dystrophy. AVI's NeuGene compounds
are also designed to treat cardiovascular restenosis in stent and
coronary artery bypass graft (CABG) procedures. In addition to
targeting specific genes in the body, AVI's antiviral program uses
NeuGene antisense compounds to combat disease by targeting
single-stranded RNA viruses, including Marburg Musoke and Ebola
Zaire viruses. More information about AVI is available at
www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
The information contained in this press release does not
necessarily reflect the position or the policy of the Government
and no official endorsement should be inferred.
AVI Press and Investor Contact: Michael Hubbard (Email Contact)
Director of Corporate Communications (503) 227-0554
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024